ESR1 and breast carcinoma: A study by Ayca Gucalp et al. observed that bicalutamide in ER negative and AR positive breast cancer demonstrated improved progression-free survival [22], lending further support that AR or its signalling pathways may be a tangible route for treating patients in the ER negative subgroup.